the aid library

LIST OPTIONS

Filter

8562

Buruli Ulcer Prevention of Disability (POD)
recommended

Linda Lehman, Valérie Simonet, Paul Saunderson, and Pius Agbenorku World Health Organization WHO (2006) C_WHO

This manual is for use by doctors, nurses, rehabilitation specialists, National Buruli ulcer Control Programme managers and other health workers involved in the prevention of disability activities in Buruli ulcer. You can download chapters and presentations

Download (635)

View PDF (687)

Contextual Factors Influencing Modern Contraceptive Use in Nigeria

Ejembi, Clara Ladi, Tukur Dahiru, and Alhaji A. Aliyu ICF International (2015) C2

DHS Working Papers No. 120

Download (405)

View PDF (488)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Download (272)

View PDF (265)

Statement to African Union Member States on the deployment of the AstraZeneca COVID-19 Vaccine to the continent and concerns about adverse event reports coming from Europe

African Union; Africa CDC Centres for Disease Control and Prevention; World Health Organization WHO, et al. (2021) CC

19 March 2021

Download (577)

View PDF (842)

Factors Associated with Changes in Uptake of HIV Testing among Young Women (age 15–24) in Tanzania from 2003 to 2012

Phimemon, Rune N., Michael J. Mahande, and Habib O. Ramadhani ICF International (2015) C2

DHS Working Papers No. 119

Download (429)

View PDF (538)

Planning, Monitoring and Evaluation. Webinar 14. Companion Technical Booklet

Mont, D. UNICEF (2014)

Download (507)

View PDF (729)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (625)

View PDF (889)

India: Guidelines for the Public Private Partnership Model of ART centres

National AIDS Control Organisation (NACO), Government of India (2017) C1

Download (536)

View PDF (909)

Interim Guidance for Protecting Workers from Occupational Exposure to Zika Virus

Centers for Disease Prevention and Control CDC OSHA; NIOSH (2016) C_CDC

Download (295)

View PDF (255)

Global Fund Overview

The Global Fund to Fight AIDS, Tuberculosis and Malaria The Global Fund to Fight AIDS, Tuberculosis and Malaria (2020) C2

Accessed: 10.03.2020

Download (481)

View PDF (606)

The Global Status Report on Preventing Violence Against Children 2020

UNICEF WHO (2020) C_WHO

As this report shows, reports of child abuse and of children witnessing violence between their parents and caregivers have increased. Ending violence against children is increasingly within our reach. D

Download (353)

View PDF (338)

A Field Guide to Antibiotic Stewardship in Outpatient Settings

Telligen, Quality Innovation Network National Coordinating Center, Centers for Medicare & Medicaid Services (CMS) (2018) C2

Antibiotic Stewardship (AS) is a coordinated program that promotes the appropriate use of antimicrobials to improve patient outcomes, reduce microbial resistance, and decrease the spread of multi-drug resistant organisms. In clinical settings, stewardship activities focus on measuring and improving ... more

Download (295)

View PDF (390)

More than money — The Joint United Nations Programme on HIV/AIDS and the Global Fund to Fight AIDS, Tuberculosis and Malaria

The Global Fund, UNAIDS UNAIDS (2021) C_WHO

Joint actions by the Global Fund and UNAIDS are guided by a strong alignment of strategies, goals and targets. UNAIDS has worked with all stakeholders to set a common agenda and targets within the Global AIDS Strategy 2021–2026, and the United Nations General Assembly confirmed this strategy and i... more

Download (371)

View PDF (507)

Inequality Kills (Arabic Version)

Oxfam (2022) CC

The unparalleled action needed to combat unprecedented inequality in the wake of COVID-19. New billionaire minted every 26 hours, as inequality contributes to the death of one person every four seconds

External Link

Strengthening the collection, analysis and use of health workforce data and information: a handbook

World Health Organisation (WHO) (2023) C_WHO

Access to health workers who are fit for purpose, motivated and protected is a fundamental force of health service delivery and the achievement of universal health coverage and the health and health-related Sustainable Development Goals. Data and knowledge of the distribution, skill mix and future d... more

Download (251)

View PDF (264)

COVID-19 Social Media Support Kit
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2020) CC

These campaign support materials have been developed and shared to bolster national initiatives and outreach campaigns in AU Member States. The message will continue to evolve as the COVID-19 pandemic progresses and as understanding of optimal responses develop further. You can download the toolkit... more

Download (378)

View PDF (656)

WHO strategic action and resource requirements to end the acute phase of the COVID-19 pandemic 2021

World Health Organization WHO (2021) C_WHO

WHO has a unique combination of technical public health and scientific expertise, and a global operational footprint, with field offices in more than 150 countries. In 2020, this global, technical, and operational reach meant WHO was able to support countries around the world in every aspect of COVI... more